
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock between February 9 and 13, 2024, may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Company Background and Allegations - Metagenomi presented itself as a "genetic medicines company" with a significant partnership with Moderna during its IPO [4] - The collaboration with Moderna included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple research programs [4] - Following the IPO, Metagenomi announced the termination of its collaboration with Moderna on May 1, 2024, leading to claims of investor damages when the true details became public [4]